New Drugs Being Explored in Kidney Cancer
The phase 1 LITESPARK-001 trial evaluated Welireg (belzutifan) monotherapy in patients with locally advanced or metastatic solid sporadic clear cell RCC (ccRCC) who received at least one prior treatment for ccRCC, had measurable disease per RECIST v1.1 criteria, and were able to perform all of most of their daily tasks independently.
The article discusses emerging therapeutic strategies for renal cell carcinoma (RCC), including novel small‑molecule inhibitors, antibody‑drug conjugates, and radioligand therapies, highlighting ongoing clinical trials and early efficacy signals.
This claim underscores the preliminary clinical activity of belzutifan—an HIF‑2α inhibitor—in previously treated RCC patients, suggesting a potential new therapeutic option for a disease with limited responses to current targeted regimens.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)